

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Orbifloxacin Solid Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Reproductive toxicity : Category 2

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 8.1 | 2025/04/14 | 801084-00020 | 2024/09/28 |
| | | | Date of first issue: 2016/07/15 |

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and out-
lines of the emergency as-
sumed

: Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of
the skin.
May form explosive dust-air mixture during processing, han-
dling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) | ENCS No. |
|--------------------|-------------|-----------------------|----------|
| Orbifloxacin | 113617-63-3 | $\geq 3 - < 10$ | - |
| Magnesium stearate | 557-04-0 | $\geq 1 - < 10$ | 2-611 |

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-
vice immediately.
When symptoms persist or in all cases of doubt seek medical
advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty
of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms
and effects, both acute and
delayed : Contact with dust can cause mechanical irritation or drying of
the skin.
Dust contact with the eyes can lead to mechanical irritation.
Suspected of damaging the unborn child.

Protection of first-aiders : First Aid responders should pay attention to self-protection,
and use the recommended personal protective equipment
when the potential for exposure exists (see section 8).

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and dis-

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. |
| Avoidance of contact | : | Oxidizing agents |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

Storage

- | | | |
|-----------------------------|---|--|
| Conditions for safe storage | : | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Strong oxidizing agents |
| Packaging material | : | Unsuitable material: None known. |

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Concentration standard / Permissible concentration | Basis |
|--------------------|-------------|-------------------------------------|---|----------|
| Orbifloxacin | 113617-63-3 | TWA | 0.2 mg/m ³ (OEB 2) | Internal |
| Magnesium stearate | 557-04-0 | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

| | | |
|--|---|---|
| Melting point/freezing point | : | No data available |
| Boiling point, initial boiling point and boiling range | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Lower explosion limit and upper explosion limit / flammability limit | | |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Flash point | : | Not applicable |
| Decomposition temperature | : | No data available |
| pH | : | No data available |
| Evaporation rate | : | No data available |
| Auto-ignition temperature | : | No data available |
| Viscosity | | |
| Viscosity, kinematic | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Vapour pressure | : | No data available |
| Density and / or relative density | | |
| Relative density | : | No data available |
| Density | : | No data available |
| Relative vapour density | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Particle characteristics
Particle size : No data available

10. STABILITY AND REACTIVITY

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Orbifloxacin:**

| | | |
|---|---|---|
| Acute oral toxicity | : | LD50 (Rat): > 3,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Mouse): > 2,000 mg/kg Remarks: No mortality observed at this dose. LD50 (Dog): > 600 mg/kg Symptoms: Vomiting Remarks: No mortality observed at this dose. |
| Acute inhalation toxicity | : | Remarks: No data available |
| Acute dermal toxicity | : | Remarks: No data available |
| Acute toxicity (other routes of administration) | : | LD50 (Rat): > 200 mg/kg Application Route: Intramuscular LD50 (Mouse): 500 mg/kg Application Route: Intramuscular |

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Orbifloxacin:**

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Orbifloxacin:**

Species : Rabbit
Result : Mild eye irritation
Method : Draize Test

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Orbifloxacin:**

| | |
|-----------------|--------------------------|
| Test Type | : Maximisation Test |
| Exposure routes | : Dermal |
| Species | : Guinea pig |
| Result | : Not a skin sensitizer. |

Magnesium stearate:

| | |
|-----------------|--|
| Test Type | : Maximisation Test |
| Exposure routes | : Skin contact |
| Species | : Guinea pig |
| Method | : OECD Test Guideline 406 |
| Result | : negative |
| Remarks | : Based on data from similar materials |

Germ cell mutagenicity

Not classified based on available information.

Components:**Orbifloxacin:**

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal |
|-----------------------|---|

| | |
|--|---|
| | Test Type: Mouse Lymphoma Result: positive |
|--|---|

| | |
|--|---|
| | Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive |
|--|---|

| | |
|----------------------|--|
| Genotoxicity in vivo | : Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intraperitoneal injection Result: negative |
|----------------------|--|

| | |
|--|---|
| | Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative |
|--|---|

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Orbifloxacin:**

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Orbifloxacin:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat

Orbifloxacin Solid Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 8.1 | Revision Date: 2025/04/14 | SDS Number: 801084-00020 | Date of last issue: 2024/09/28 Date of first issue: 2016/07/15 |
|----------------|------------------------------|-----------------------------|---|

Application Route: Oral
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight
Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:**

Orbifloxacin:

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

| | |
|-------------------|---------------------------------|
| Species | : Rat |
| NOAEL | : 20 mg/kg |
| LOAEL | : 80 mg/kg |
| Application Route | : Oral |
| Exposure time | : 3 Months |
| Target Organs | : Testis, Liver, Kidney, spleen |

| | |
|-------------------|-------------|
| Species | : Mouse |
| NOAEL | : 80 mg/kg |
| LOAEL | : 250 mg/kg |
| Application Route | : Oral |
| Exposure time | : 3 Months |

| | |
|-------------------|--------------------------------|
| Species | : Juvenile dog |
| NOAEL | : 50 mg/kg |
| LOAEL | : 250 mg/kg |
| Application Route | : Oral |
| Exposure time | : 14 Days |
| Target Organs | : Heart, Bone |
| Symptoms | : Gastrointestinal disturbance |
| Remarks | : mortality observed |

| | |
|-------------------|--|
| Species | : Juvenile dog |
| NOAEL | : 2 mg/kg |
| LOAEL | : 3 mg/kg |
| Application Route | : Oral |
| Exposure time | : 90 Days |
| Target Organs | : Bone |
| Remarks | : No significant adverse effects were reported |

| | |
|-------------------|--------------|
| Species | : Dog |
| NOAEL | : 37.5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 30 Days |

| | |
|-------------------|--------------------------------|
| Species | : Cat |
| NOAEL | : 7.5 mg/kg |
| LOAEL | : 22.5 mg/kg |
| Application Route | : Oral |
| Exposure time | : 1 Months |
| Symptoms | : Gastrointestinal disturbance |

Magnesium stearate:

| | |
|-------------------|--|
| Species | : Rat |
| NOAEL | : > 100 mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 90 Days |
| Remarks | : Based on data from similar materials |

Aspiration toxicity

Not classified based on available information.

Orbifloxacin Solid Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 8.1 | Revision Date: 2025/04/14 | SDS Number: 801084-00020 | Date of last issue: 2024/09/28 Date of first issue: 2016/07/15 |
|----------------|------------------------------|-----------------------------|---|

Experience with human exposure**Components:****Orbifloxacin:**

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitisation.

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Magnesium stearate:**

| | |
|---|---|
| Toxicity to fish | : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials |
| Toxicity to daphnia and other aquatic invertebrates | : EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility |
| Toxicity to algae/aquatic plants | : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials |
| Toxicity to microorganisms | : EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials |

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Persistence and degradability**Components:****Magnesium stearate:**

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Orbifloxacin Solid Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 8.1 | Revision Date: 2025/04/14 | SDS Number: 801084-00020 | Date of last issue: 2024/09/28 Date of first issue: 2016/07/15 |
|----------------|------------------------------|-----------------------------|---|

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

| Chemical name | Concentration (%) | Remarks |
|--------------------|-------------------|---------|
| Magnesium stearate | ≥ 1 - < 10 | - |

Substances Subject to be Indicated Names

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

| Chemical name | Remarks |
|--------------------|---------|
| Magnesium stearate | - |

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2024/09/28 |
| 8.1 | 2025/04/14 | 801084-00020 | Date of first issue: 2016/07/15 |

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN